Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.67, $0.24 better than the analyst estimate of $3.43. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.31 billion.

GUIDANCE:

Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.49.

For earnings history and earnings-related data on Biogen (BIIB) click here.